NEW YORK (GenomeWeb News) – Covance and NeoGenomics today announced a collaboration to jointly offer anatomic pathology and specialty laboratory testing services for clinical trials.
Covance will create a laboratory at NeoGenomics' facility in Fort Myers, Fla., and together they will provide a full range of anatomic pathology and histology services, including immunohistochemistry, fluorescence in situ hybridization, molecular testing, as well as tissue-based biomarkers and other specialty testing services.
Joint capabilities will then be expanded at Covance's labs in Shanghai, Geneva, and Singapore.
The deal provides Covance access to NeoGenomics' medical and scientific networks, which include more than 500 pathologists, while NeoGenomics will have access to Covance's market reach, client relationships, and clinical trial experience, the companies said. They added that the alliance will provide global testing services to support oncology and companion diagnostics strategies for biopharmaceutical companies.
"The collaboration with NeoGenomics will offer our clients fully integrated anatomic pathology services from sample preparation, staining and imaging, to pathology interpretation by leading pathologists, in an end to end manner," Paul Kirchgraber, vice president of laboratory operations & medical affairs for Covance Central Laboratory Services, said in a statement. "Providing these integrated services through the Covance laboratory co-located within NeoGenomics results in improved turnaround times critical to oncology clinical trials."
Financial and other terms of the deal were not disclosed.
Cancer genetics testing company NeoGenomics said recently that revenues in its third quarter increased 19 percent year over year to $16.9 million.